PRINCETON, New Jersey, Jan. 5, 2016 /PRNewswire/ -- GalbraithWight, a global market access consultancy, announces the launch of Apollo LX, the first & only global Launch Excellence planning application with GalbraithWight's Market Access and Launch Planning expertise embedded in its platform.
72% of new medicines are a commercial 'flop'1 & a row of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly tough Payer reimbursement environment2.
According to CEO & market access expert, Colin Wight, "Outside of product failure, major reasons for launch failure include planning too late, lack of communication between functions & between HQ & country teams & worst of all, failure to address the vital Payer requirements for market access early enough, resulting in a last minute scramble to fix something that could have been foreseen."
It costs $2.5 billion to develop a new medicine3, so it makes sense to ensure every launch has the best possible chance of success, more patients get access to life saving or life enhancing medicines they deserve, & investors get the returns they are expecting.
That is why GalbraithWight has launched Apollo LX.
Apollo LX is specifically designed for pharmaceutical & biotech launch planning, and comes fully loaded with GalbraithWight's global market access & launch planning framework – everything you need to develop & implement a highly successful launch.
Apollo LX is an easy-to-use web application that provides global visibility and control of brand launches across the enterprise to improve communication between functions and between HQ & countries.
Apollo LX provides launch planning, communication & tracking, with ultimate user ease, clarity and control to create launch success, so with Apollo LX, launch excellence can now be a reality.
See more about Apollo LX at www.apollolx.com
A global market access consultancy with almost 20 years successful Consulting & Training experience, a team of expert Consultants with extensive senior level international strategic & operational experience, plus proven capability delivering solutions on the ground throughout North & South America, Europe, Asia Pacific & the Middle East & Africa. GalbraithWight has worked on many major brands, including Yervoy, Lenvima, Opdivo, Ibrance, Eliquis, Gardasil, Forxiga, Empliciti, Sivextro, Zerbaxa and many others. GalbraithWight has offices in Princeton, NJ & Milan, Italy.